Form 4/A for DFTX Definium Therapeutics, Inc.
Accepted 2022-05-19 00:00:00 ET · period of report 2022-05-18 · accession 0001209191-22-030499 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-05-19 | 2022-05-18 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $0.71 | -18.9K | 4.00M | -0.5% | -$13.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Subordinate Voting Shares | 2022-05-18 | S | D | 18,948 | $0.71 | 3,995,309 | D | — | — | (F2) The Subordinate Voting Shares were sold in one transaction at a price of $0.92 CAD Dollars. This represents the price in United States Dollars using the conversion rate on May 18, 2022. |